Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cytran

Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are HIV-positive.

• Have AIDS-related Kaposi's sarcoma.

• Have at least 5 skin or mouth sores that do not require chemotherapy.

• Have been taking anti-HIV drugs for at least 8 weeks before study entry with no changes in the regimen.

• Are at least 18 years old.

• Agree to practice effective methods of birth control.

Exclusion Criteria

Patients will not be eligible for this study if they:

• Have an AIDS-related opportunistic infection (except for genital herpes) within 2 weeks of study entry.

• Have had another type of cancer within the past 2 years (except for certain types of skin cancer, cervical cancer, or anal cancer).

• Have a severe chest cold.

• Have certain other serious medical conditions.

• Have received certain medications, including chemotherapy, within the past 4 weeks.

• Abuse alcohol or drugs.

• Are pregnant or breast-feeding.